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MaOBJECTIVES This study introduces a newly designed transcatheter aortic valve system, the J-Valve system, and
evaluates its application in patients with predominant aortic regurgitation without signiﬁcant valve calciﬁcation. We also
report the early results of one of the ﬁrst series of transapical implantations of this device and aim to offer guidance on
the technical aspects of the procedure.
BACKGROUND Transcatheter aortic valve replacement (TAVR) has been widely used in high-risk patients for surgical
aortic valve replacement. However, themajority of the TAVR deviceswere designed for aortic valve stenosis with signiﬁcant
valve calciﬁcation.
METHODS Six patients with native aortic regurgitation without signiﬁcant valve calciﬁcation (age, 61 to 83 years; mean
age, 75.50  8.14 years) underwent transapical implantation of the J-Valve prosthesis (JieCheng Medical Technology Co.,
Ltd., Suzhou, China), a self-expandable porcine valve, in the aortic position at our institution. All patients were considered
to be prohibitive or high risk for surgical valve replacement (logistic EuroSCORE [European System for Cardiac Operative
Risk Evaluation], 22.15% to 44.44%; mean, 29.32  7.70%) after evaluation by an interdisciplinary heart team. Proce-
dural and clinical outcomes were analyzed.
RESULTS Implantations were successful in all patients. During the follow-up period (from 31 days to 186 days, mean
follow-up was 110.00  77.944 days), only 1 patient had trivial prosthetic valve regurgitation, and none of these patients
had paravalvular leak of more than mild grade. There were no major post-operative complications or mortality during the
follow-up.
CONCLUSIONS Our study demonstrated the feasibility of transapical implantation of the J-Valve system in high-risk
patients with predominant aortic regurgitation. (J Am Coll Cardiol Intv 2015;8:1831–41) © 2015 by the American College
of Cardiology Foundation.T ranscatheter aortic valve replacement(TAVR) has been proved to be an effectivetreatment of aortic valve disease in patients
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ABBR EV I A T I ON S
AND ACRONYMS
MSCT = multislice computed
tomography
TAVR = transcatheter aortic
valve replacement
TEE = transesophageal
echocardiography
THV = transcatheter heart
valve
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1832been used. However, for most of these de-
vices, predominant aortic regurgitation
remained to be a technological challenge
because of questionable anchoring, which
can result in a high incidence of valve
migration and paravalvular leak. Conse-
quently, the guidelines from the United
States and the Europe suggest that candi-
dates with predominant aortic regurgitation
(>grade 3þ) or noncalciﬁed valve should notundergo TAVR (1,2).
Patients with predominant aortic regurgitation
who are at prohibitive risk for surgery need an alter-
native treatment. A new generation of transcatheter
aortic valve devices with secure anchoring is needed.SEE PAGE 1850The off-label use of the current devices in aortic
regurgitation has been sporadically reported and in-
cludes the SAPIEN valve, CoreValve, JenaValve
(JenaValve Technology GmbH, Munich, Germany),
and Engager Aortic Valve bioprosthesis (Medtronic)
(3–8).
The J-Valve system (JieCheng Medical Technology
Co., Ltd., Suzhou, China) is a new generation of
transcatheter heart valve (THV) with a unique design
of a 2-piece structure that consists of a 3-prong
clasper and a support frame. This distinctive design
allows the THV to be implanted in 2 stages, which
results in precise anatomic positioning and secure
anchoring.
We introduce the J-Valve system and report the
feasibility and early results of TAVR in 6 patients with
predominant aortic regurgitation.
METHODS
PATIENT POPULATION AND DIAGNOSTIC WORKUP.
The TAVR program at the Department of Cardiovas-
cular Surgery, Zhongshan Hospital, began at May
2014. Between May and December 2014, 16 patients
were chosen for TAVR. Ten patients presented with
symptomatic severe aortic valve stenosis with signif-
icant calciﬁed valves. Six patients presented with
symptomatic predominant aortic regurgitation
without signiﬁcant valve calciﬁcation. All 16 patients
were evaluated by the heart team before admission
and considered to be at prohibitive or high risk for
surgical aortic valve replacement. In addition to a
routine workup, transthoracic echocardiography and
contrast-enhanced multislice computed tomography
(MSCT) were performed. The degree of the aortic
regurgitation was graded by transthoracic echocardi-
ography based on the vena contracta width. Thediameter of the aortic annulus was measured in the
short axis. MSCT was performed to assess the
morphology of the aortic valve and root (Figure 1A).
The diameter of the aortic annulus for sizing the
prosthesis was calculated by measuring the area of the
native aortic valve and the perimeter of the annulus
(Figure 1B). Patients were placed in the supine posi-
tion when MSCT scans were performed, which is the
same position as for TAVR procedures. Three-
dimensional images of the aortic root with proximal
segments of left and right coronary arteries in
different angles were reconstructed to determine
the optimal C-arm angulations (Figure 1C). Two-
dimensional images were reconstructed to measure
the angulations between the long axis of the
aortic root and the left ventricular outﬂow tract,
which helps to determine the optimal curvature of the
delivery system during the procedures (Figure 1D).
Two-dimensional images were also reconstructed to
measure the distance between the ostia of coronary
arteries and the annulus (Figures 1E and 1F). The de-
tails of coronary arteries were reconstructed to rule
out signiﬁcant coronary stenosis.
PROCEDURE. The procedures were performed in a
hybrid operating room with patients under general
anesthesia with a single-lumen endotracheal tube. A
balloon-tipped bipolar endocardial temporary pacing
catheter (St. Jude Medical, St. Paul, Minnesota) was
inserted through left internal jugular vein into the
right ventricle under ﬂuoroscopic guidance. A pul-
monary artery catheter was inserted through right
internal jugular vein for hemodynamic monitoring.
Transesophageal echocardiography (TEE) was per-
formed to further conﬁrm aortic regurgitation and the
annulus diameter (Figure 2A). The size of the pros-
thesis was determined by the diameter of aortic
annulus. Cardiopulmonary bypass was available as a
standby during all procedures.
The prosthesis and delivery system were assem-
bled after the size of the prosthesis was conﬁrmed.
The projection of left ventricle apex on the chest wall
was localized under ﬂuoroscopy to determine the
optimal incision. A 5-F introducer was inserted in the
common femoral artery followed by insertion of a 5-F
AltaFlow pigtail measuring catheter (OptiMed, Etlin-
gen, Germany), which was positioned in the aortic
root. A limited left anterolateral thoracotomy was
performed in the ﬁfth or sixth intercostal space ac-
cording to the projection of ventricle apex. After 2
3-0 polypropylene (Ethicon, Somerville, New Jersey)
Teﬂon-reinforced mattress sutures placed on the
ventricle apex, 1 mg/kg heparin was administered to
keep the activated clotting time at more than 300 s.
FIGURE 1 Pre-Operative MSCT
Pre-operative MSCT (patient 2) to evaluate the anatomy of the aortic root. (A) The morphology of the aortic valve at the level of commissures.
(B) The perimeter and area of the aortic annulus were measured to estimate the diameter of the annulus. (C) The volume-rendering image of
the aortic root and coronary arteries in which the left and right aortic sinuses are symmetrical and the nadirs of the 3 sinuses are in a tangential
plane. (D) The long-axis reconstruction image of the left ventricle, which presents the angulations between the long axis of aortic root and left
ventricular outﬂow tract. (E, F) The distances between the ostia of both coronary arteries and the annulus were measured. Circ ¼ circum-
ference; MSCT ¼ multislice computed tomography.
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1833The C-arm was set at the optimal angle, and an aortic
root angiogram was performed (Figure 3A). By pre-
operative MSCT, reference angulation of the C-arm
was provided perpendicularly in relation to the aortic
annulus. A reference line through the nadirs of aortic
sinuses was marked on the screen to localize the
annulus plane. The positions of the C-arm and the
operating table were maintained until the implanta-
tion was completed.
A soft hydrophilic Radiofocus guidewire (Terumo,
Tokyo, Japan) was inserted in the ventricle apex and
used to cross the aortic valve and then positioned in
the ascending aorta. The hydrophilic guidewire was
exchanged for a standard polytetraﬂuoroethylene-
coated EMERALD guidewire (Cordis Johnson &
Johnson, Miami Lakes, Florida), and the latter was
positioned across the aortic arch and down into the
descending aorta with the guidance of a right Judkins
catheter (Cordis Johnson & Johnson).
A small incision w5 mm long was made next to the
guidewire to facilitate insertion of the deliverysystem. The size of the delivery sheath was 27-F. Four
knobs in the delivery system controlled the deploy-
ment of the clasper, lowering, deployment, and
release of the prosthesis.
The delivery system was inserted in the left
ventricle and across the aortic valve without an
apical sheath. Implantation was performed in 2
stages and was monitored by both ﬂuoroscopy and
TEE. The ﬁrst stage was positioning the clasper. The
clasper was deployed in the aortic root (Figure 3B,
Online Video 1). As the surgeon gently pulled back
the delivery system, the clasper would be seated in
the aortic sinuses, and then an aortic root angiogram
was obtained to conﬁrm the position of the clasper
(Figure 3C, Online Video 2). The second stage was
lowering and deployment of the prosthesis. The
prosthetic valve was lowered into the aortic annulus
and then deployed without rapid pacing (Figures 3D
and 3E, Online Videos 3 and 4). The prosthesis
was then released, and the delivery system
was removed. The step-by-step implantation was
FIGURE 2 TEE During the Procedure
TEE (Patient #2) before and after implantation of the prosthesis. (A) TEE showed a grade 3þ central aortic regurgitation before prosthesis
implantation. (B) TEE after prosthesis implantation. (C) TEE showed no paravalvular leak after the prosthesis implantation. TEE ¼ trans-
esophageal echocardiography.
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1834demonstrated in a heart model in vitro (Figure 4).
Functioning of the prosthesis was assessed by TEE
immediately (Figures 2B and 2C). After the guidewire
was removed, the apical sutures were tied, and 1.5FIGURE 3 Step-by-Step Implantation
Step-by-step transapical implantation (Patient #6) of a 27-mm J-Valve
(A) An aortic root angiogram depicts the morphology of the aortic sinus
(Online Video 1). (C) Repeat aortic root angiography was performed to con
valve was lowered into the aortic annulus and was deployed there (Onl
paravalvular leak (Online Video 5).mg/kg protamine was administered. Then hemosta-
sis was achieved. A ﬁnal aortic root angiogram was
obtained to assess the prosthesis function and to
conﬁrm that both coronary ostia were patentprosthesis (JieCheng Medical Technology Co., Ltd., Suzhou, China).
es and coronary ostia. (B) The clasper was deployed in the aortic root
ﬁrm the position of the clasper (Online Video 2). (D, E) The prosthetic
ine Videos 3 and 4). (F) A ﬁnal aortic root angiogram showed no
FIGURE 4 Step-by-Step Implantation Demonstration In Vitro
Step-by-step implantation of the J-Valve prosthesis (JieCheng Medical Technology Co., Ltd.) in a heart model in vitro. (A) The top of the delivery system is passed
through the aortic oriﬁce into the aortic root. (B) The clasper was deployed in the aortic root. (C) The clasper was positioned into the aortic sinus. (D) The prosthetic valve
was lowered into the aortic annulus. (E) The prosthetic valve was deployed in the aortic annulus.
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1835(Figure 3F, Online Video 5). The incision was closed
in routine fashion. Post-operative device-speciﬁc
medical therapy consisted of daily warfarin to keep
the international normalized ratio between 2.0 and
3.0 for at least 6 months.FIGURE 5 Post-Operative MSCT
The post-operative MSCT (Patient #2). (A, B) The short-axis reconstruct
annulus. (C, D) The long-axis reconstruction showing the position of the
(E, F) The 2- and 3-dimensional reconstructions showing the prosthesisDATA MANAGEMENT AND CLINICAL FOLLOW-UP.
All relevant baseline, procedural, and follow-up
data were prospectively collected. Clinical and
echocardiographic examinations were performed
before discharge and at 30 days, 3 months, and 1 yearion showing the support frame at the level of the commissures and
prosthesis and its relationship with the left and right coronary ostia.
in the aortic root. MSCT ¼ multislice computed tomography.
TABLE 1 Detailed Pa
Patient #
Age,
yrs Se
1 79 Fem
2 83 Fem
3 79 Ma
4 80 Ma
5 61 Ma
6 71 Ma
BMI ¼ body mass index; log
mitral regurgitation; NYHA
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1836after the procedure. MSCT was performed before
discharge as well (Figure 5). Outcomes were analyzed
in accordance with the updated standardized end-
points deﬁned by the Valve Academic Research
Consortium-2 (9).
ETHICS. The J-Valve China Trial 2014 was approved
by China Food and Drug Administration. The local
ethics committee approved the study protocol at our
center. The study was registered with the Chinese
Clinical Trial Registry (ChiCTR-OPC-15006354). All
patients were fully informed about the procedure and
its experimental use of the THV (at the time of im-
plantation). All patients signed written consent
forms.
STATISTICS. This was a descriptive study with 6 pa-
tients. No inferential statistical analyses were per-
formed. Continuous variables were presented as
mean  SD. All statistical analyses were performed
with SAS version 9.2 (SAS Institute Inc., Cary, North
Carolina).
RESULTS
BASELINE CHARACTERISTICS. Six patients (mean
age, 75.5  8.0 years; 66.7% men) who presented
with predominant aortic regurgitation were chosen
for the study. All patients had symptoms of left
ventricular dysfunction. All the aortic valves were
tricuspid. Only 1 patient had mild aortic valve ste-
nosis. No patients had signiﬁcant mitral valve
dysfunction. All patients were in sinus rhythm
without any conduction abnormalities. One patienttient Characteristics
x
BMI,
kg/m2
Log ES,
%
NYHA
Functional
Class Comorbidities
ale 24.67 22.15 III Left ventricular dysfunction, neurological
dysfunction, systemic hypertension
ale 22.83 27.08 III Impaired glucose tolerance, left ventricul
dysfunction, neurological dysfunction
systemic hypertension
le 19.53 27.97 III Chronic pulmonary disease, neurological
dysfunction, systemic hypertension,
unstable angina
le 17.82 44.44 III Chronic pulmonary disease, extracardiac
arteriopathy, neurological dysfunction
systemic hypertension, unstable angin
le 18.75 26.78 IV Chronic pulmonary disease, critical pre-o
state, extracardiac arteriopathy, left
ventricular dysfunction, unstable ang
le 22.99 27.50 III Coronary artery disease, neurological
dysfunction, previous cardiac surgery
systemic hypertension, unstable angin
ES ¼ logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE); LVEDD¼
¼ New York Heart Association; PAP ¼ systolic pulmonary artery pressure; TR ¼ tricuspid rhad a history of off-pump coronary artery bypass
surgery. Pre-operatively, all patients were evaluated
by an interdisciplinary heart team and deemed to
be at prohibitive or high risk for surgical aortic
valve replacement due to comorbidities. The mean
logistic EuroSCORE (European System for Cardiac
Operative Risk Evaluation) of these patients was
29.32  7.70%. Detailed patient characteristics are
listed in Table 1. The baseline morphology and pa-
thology of the aortic roots and valves are listed in
Table 2.
PROCEDURAL OUTCOMES AND VALVE FUNCTION.
The implantations of the J-Valve prosthesis in all
patients were successful. All procedures were per-
formed without the need of rapid pacing or cardio-
pulmonary bypass. No pre- or post-dilation was
performed. There was no conversion to open surgery.
No coronary obstructions or valve malpositioning
occurred.
The amount of contrast varied from 60 to 138 ml in
each case (mean dose, 86.33  34.42 ml). After pre-
operative MSCT was introduced to determine the
optimal angle for angiography, the contrast dose
was reduced to w60 ml. The skin-to-skin procedure
time varied from 78 to 150 min (mean time, 101.67 
26.311 min).
The appropriate size of the prosthesis was deter-
mined to be 5% to 10% larger than the native annulus
diameter. Based on the aortic annulus diameter
measured by MSCT and TEE, 3 25-mm and 3 27-mm
prostheses were implanted. Hemostasis was easily
achieved in all cases without signiﬁcant blood loss.Creatinine,
mg/dl
PAP,
mm Hg MR Grade TR Grade
LVEF,
%
LVEDD,
mm
1.1 40 Mild Mild 69 49
ar
,
0.8 35 Mild Trivial 50 48
1.3 30 Trivial Trivial 60 56
,
a
1.0 40 None Trivial 60 51
perative
ina
1.0 40 Trivial Trivial 47 57
,
a
1.0 40 Trivial Trivial 69 52
left ventricular end-diastolic diameter; LVEF ¼ left ventricular ejection fraction; MR ¼
egurgitation.
TABLE 2 Baseline Morphology and Pathology of the Aortic Root and Aortic Valve
Patient #
Aortic Annulus Diameter STJ Diameter
Aortic Valve Pathology AR Grade
Vena Contracta
Width, mm
Jet Width/
LVOT
Width, %
VG Mean,
mm Hg
EOA,
cm2
MSCT
Area–Derived,
mm
MSCT
Perimeter–Derived,
mm
TEE,
mm
MSCT,
mm
1 21.47 23.57 21 30.5 Central AR, degenerative Moderate to severe 4 31.58 0 3.5
2 22.23 23.25 20 29.6 Central AR, leaﬂet
calciﬁcation
Moderate to severe 5.7 50 0 3.4
3 25.34 26.75 24 38.1 Central AR, leaﬂet
calciﬁcation
Moderate to severe 5.7 54.55 12 1.6
4 24.42 25.16 22 46.1 Central AR, leaﬂet
calciﬁcation,
root dilation
Severe 7 70 0 4.0
5 21.77 26.11 24 36.3 Eccentric AR, right cusp
contracture
Severe 8 70 0 2.9
6 25.16 27.07 24 32.3 Central AR, sclerotic
alterations, thickened tip
Moderate to severe 5.5 48 0 3.4
AR ¼ aortic regurgitation; EOA ¼ effective oriﬁce area; LVOT ¼ left ventricular outﬂow tract; MSCT ¼multislice computed tomography; STJ ¼ sinotubular junction; TEE ¼ transesophageal echocardiography;
VG ¼ transvalvular gradient.
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1837The functioning of the prostheses was assessed
immediately after implantations by TEE and angiog-
raphy. There was no regurgitation or stenosis of the
implanted valves immediately after the procedure in
all cases. The mean transvalvular gradient was 6.0 
1.8 mm Hg. None of the cases had signiﬁcant para-
valvular leak. Detailed valve function data immediate
after implantation are listed in Table 3.
CLINICAL OUTCOMES AND FOLLOW-UP. The ﬁrst
patient was extubated in the operating room, and the
other 5 patients were extubated in the intensive care
unit on the ﬁrst post-operative day. The mean length
of intensive care unit stay and post-operative hospital
stay was 2.17  1.329 days and 6.00  1.789 days,
respectively. The mean drainage in the ﬁrst 24 h after
surgery was 35.00  38.859 ml. All patients were
followed for at least 30 days (range, 31 to 186 days;
mean, 110.00  77.94 days).
There were no mortality or major post-operative
complications during the hospital stay and follow-up.
In the latest follow-up, all patients were New YorkTABLE 3 Detailed Valve Function Immediate After Implantation
Patient #
THV Size,
mm AR Grade PVL Grade
VG Mean,
mm Hg
EOA,
cm2
LVEDD,
mm
1 25 0 None 7 1.9 43
2 25 0 None 5 2.3 47
3 27 0 Mild 9 2.1 47
4 27 0 Trace 5 2.5 43
5 25 0 Trace 7 1.9 52
6 27 0 Trace 4 2.8 48
PVL ¼ paravalvular leak; THV ¼ transcatheter heart valve; other abbreviations as
in Tables 1 and 2.Heart Association functional class I or II. The symp-
toms of exertional dyspnea and exercise intolerance
were signiﬁcantly improved in all cases.
Three patients had new-onset complete left bundle
branch block, and 1 patient had ﬁrst-degree atrio-
ventricular block after the procedure without brady-
cardia; 2 of the 3 patients with complete left bundle
branch block and the patient with ﬁrst-degree atrio-
ventricular block recovered spontaneously 1 month
after the procedure, whereas 1 patient remained in
left anterior fascicular block 2 months after the pro-
cedure. One patient had new-onset atrial ﬁbrillation
4 days after the procedure and converted to sinus
rhythm within 24 h after administration of amiodar-
one. No permanent pacemaker implantation was
needed. No new arrhythmia resulting in hemody-
namic instability occurred during the perioperative
period.
No neurological complications (including stroke
and transient ischemic attack) occurred during the
hospital stay and follow-up. Only 1 patient had
stage 1 acute kidney injury after the procedure
according to the Acute Kidney Injury Network
criteria (10) and recovered spontaneously soon
after discharge without the need for dialysis. No
myocardial infarction or vascular complications
occurred during the perioperative and follow-up
periods.
Transthoracic echocardiograms were obtained 1
month, 2 months, and 6 months after surgery to
evaluate the function of the implanted valves.
Detailed clinical outcomes and follow-up data are
listed in Table 4. The results of the latest echocar-
diographic follow-up are listed in Table 5.
TABLE 4 Detailed Clinical Outcomes During Hospital Stay and Follow-Up
Patient #
During Hospital Stay During Follow-Up
ICU Stay,
days
Hospital Stay,
days
Drainage in 1st 24 h,
ml
Adverse
Events
Follow-Up,
days Adverse Events
NYHA Functional
Class
1 1 6 110 LBBB, AKI 177 None II
2 3 7 20 LBBB 179 None I
3 1 5 40 AF 186 None II
4 4 9 20 LBBB 55 Left anterior fascicular block II
5 3 5 20 None 32 None II
6 1 4 0 I-AVB 31 None II
AF ¼ atrial ﬁbrillation; AKI ¼ acute kidney injury; I-AVB ¼ ﬁrst-degree atrioventricular block; ICU ¼ intensive care unit; LBBB ¼ left bundle branch block; NYHA ¼ New York
Heart Association.
Wei et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 4 , 2 0 1 5
Implantation of the J-Valve and Early Outcome D E C E M B E R 2 1 , 2 0 1 5 : 1 8 3 1 – 4 1
1838DISCUSSION
According to the latest guidelines, TAVR is recom-
mended for patients with aortic valve stenosis who
have a prohibitive risk for surgical aortic valve
replacement, and it is considered a reasonable alter-
native to surgical aortic valve replacement in patients
with aortic valve stenosis who have high surgical risk
(11). Nevertheless, TAVR in patients with predominant
aortic regurgitation has never been widely accepted.
TAVR was not recommended for patients with pre-
dominant aortic regurgitation (>grade 3þ) or non-
calciﬁed valve in recent guidelines (1,2). The off-label
use of the Edwards SAPIEN valve and Medtronic Cor-
eValve was previously reported (3–6). The risk of valve
dislocation due to insufﬁcient anchoring and annular
rupture as a consequence of excessive oversizing
limited the use of these devices in predominant aortic
regurgitation. The off-label use of the JenaValve sys-
tem in 5 patients of noncalciﬁed aortic regurgitation
was ﬁrst reported in 2013 (7). The initial German
multicenter experience with the JenaValve system for
the treatment of pure aortic regurgitationwas reported
in 2014. The deployment process of JenaValve system
consists of feeler-guided positioning and secure clip
ﬁxation. Because of the unmovable connection
between the feeler and the stent, unsatisfactory
positioning of the feeler could result in an inade-
quate alignment and suboptimal positioning of theTABLE 5 Results of Echocardiography at Follow-Up
Patient # Follow-Up, days AR Grade PVL Grade PAP, mm Hg
1 177 None None 38
2 179 None Trivial 32
3 186 Trivial Mild 33
4 55 None Mild 39
5 32 None Mild 38
6 31 None Trace 28
Abbreviations as in Tables 1 to 3.prosthesis, which might render signiﬁcant para-
valvular leak or even dislodgment of the prosthesis
(12). The need for an alternative treatment for high-risk
patients with predominant aortic regurgitation who
meet the indications for surgical aortic valve replace-
ment urged the emergence of a new-generation THV.
THE STRUCTURE OF THE J-VALVE PROSTHESIS AND
THE FUNCTION OF THE CLASPER. The J-Valve sys-
tem is a newly designed porcine valve. The leaﬂets
are mounted in a self-expanding support frame that
is connected with a 3-prong clasper by 3 sutures
(Figure 6). This unique connection makes the pros-
thetic valve be movable along the long axis of the
clasper. The structure of the clasper is designed ac-
cording to the normal anatomy of the aortic sinus.
The curved portions of the clasper accommodates the
aortic sinuses during implantation. The 3 straight
portions of the clasper are 120 apart from each other;
they can be passed through the aortic commissures
and pulled back into the subaortic space, whereas the
curved portions are situated in the aortic sinuses.
Placement of the clasper in the aortic sinuses could
provide the surgeon with tactile feedback and facili-
tate the accurate deployment of the prosthesis with
minimal radiation exposure. The clasper also helps to
reinforce the anchoring of the prosthesis by clamping
the native valve leaﬂets between it and the support
frame.MR Grade TR Grade LVEF, % LVEDD, mm VG Mean, mm Hg
Trivial Mild 68 45 7
Trivial Trivial 66 44 10
Mild Trivial 62 54 11
None Trivial 68 45 5
Mild Trivial 50 51 13
Trivial Trivial 70 48 5
FIGURE 6 Schematic Drawing of the J-Valve
The schematic drawing of J-Valve prosthesis (JieCheng Medical Technology Co., Ltd.).
(A) The support frame is connected movably with a 3-prong clasper (*) by 3 sutures
(arrow). (B) The top-down view of the J-Valve prosthesis shows the support frame sur-
round by the clasper (*).
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1839ADVANTAGES OF THE MOVABLE CONNECTION AND
THE 2-STAGE IMPLANTATION. The movable connec-
tion between the clasper and the support frame makes
it possible for a 2-stage implantation process (Figure 3,
Online Videos 1, 2, 3, 4, and 5). The ﬁrst stage is the
placement of the clasper in the aortic sinuses. The
second stage is the positioning and deployment of the
prosthesis. Because of the movable connection, the
position of the prosthetic valve could be adjusted
while the clasper has already been placed in the aortic
sinus; therefore, the prosthesis could be deployed in a
perfect position coaxially with the left ventricular
outﬂow tract even in the situation when the position
of the clasper is inﬂuenced by the abnormal structure
such as calciﬁed annulus.
INDICATIONS AND ADVANTAGES OF THE J-VALVE
SYSTEM. The unique design of the J-Valve system
makes it convenient to be implanted in predominant
regurgitant aortic valves even without valvular
calciﬁcation. In choosing candidates for this proce-
dure, it is critical to determine the diameter of the
native annulus. Patients with annulus larger than 27
mm were excluded from this study because the
maximal size of the prosthesis available is 27 mm. The
following were also contraindications for this proce-
dure: patients with congenital bicuspid aortic valve,
the diameter of the ascending aorta larger than 50
mm, and the distance between the coronary ostia and
the annulus is <5 mm.
Because of the anchoring effect of the clasper, the
risk of valve dislocation is alleviated without exces-
sive oversizing. As a result, none of the patients in
this study needed a permanent pacemaker because of
complete atrioventricular block, and the risk of
annular rupture was minimized. During the implan-
tation process in our 6 cases of predominant aortic
regurgitation, no rapid pacing or balloon expansion
was needed.
In addition to treating predominant aortic regur-
gitation, the J-Valve system could be implanted in
stenotic aortic valves with heavy calciﬁcation after
balloon valvuloplasty. We have experience with im-
plantations in 9 patients with aortic valve stenosis.
Although technical success was achieved in all cases,
iatrogenic aortic dissection from excessive balloon
valvuloplasty developed in 1 patient; the patient
fortunately survived and was discharged after re-
covery from an aortic valve and hemiarch replace-
ment surgery.
SELECTION OF THV SIZE AND FUTURE PLANS. In
this study, the THV was available in 4 sizes: 21 mm,
23 mm, 25 mm, and 27 mm. The size of the delivery
sheath was 27-F. According to our experience, it isnecessary to have 5% to 10% oversizing of the aortic
annulus derived from the MSCT-measured perimeter
to minimize the risk of paravalvular leak and insufﬁ-
cient prosthesis expansion. These 4 sizes are designed
to ﬁt an effective aortic annulus diameter by MSCT
between 19 and 26 mm. Because patients with pre-
dominant aortic regurgitation often have large
annulus, a THV of size 29 is in development. The
transaortic and transfemoral platforms are also in
development. With these new approaches, the im-
plantation might be less traumatic.
THE DIFFERENCE BETWEEN THE J-VALVE SYSTEM
AND OTHER AVAILABLE DEVICES FOR AORTIC
REGURGITATION. There were several available de-
vices on the market for aortic regurgitation such as the
JenaValve and the Engager. There were some differ-
ences between the J-Valve system and these devices.
The JenaValve has 3 nitinol feelers, which facilitated
intuitive “self-positioning” valve implantation (13).
The 3 nitinol feelers and the frame of the prosthesis are
integrated by an unmovable connection. Once each
arm of the feelers is brought into the aortic sinuses, the
position of the prosthesis could be adjusted only to a
limited extent. The stent of the Engager assembly
consists of a shaped main frame and a support frame,
which are coupled together to form the commissural
posts of the valve (14). The connection between the
main frame and the support frame is also unmovable.
Although in the J-Valve system, the clasper is
connected movably with the support frame, after the
clasper is positioned in the aortic sinuses, the posi-
tion of the prosthesis could still be adjusted upward
and downward in a direction vertical to the annulus
plane. This is quite useful when the ostia of coronary
PERSPECTIVES
WHAT IS KNOWN? TAVR in patients with predom-
inant aortic regurgitation is a technical challenge in
clinical practice. Questionable anchoring and exten-
sive oversizing would result in a high incidence of
valve migration, paravalvular leak, and conduction
system disturbance.
WHAT IS NEW? We introduced the new-generation
J-Valve prosthesis (JieCheng Medical Technology Co.,
Ltd.) and reported our experience and early outcomes
with this device in patients with predominant aortic
regurgitation. Because of the special design of
this device, accurate deployment and reinforced
anchoring of the prosthesis produced excellent early
outcomes.
WHAT IS NEXT? We believe that further study
with more cases and longer follow-up would
prove the system’s advantage in this group of
patients.
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1840arteries are close to the annulus; a lower deployment
of the prosthesis could avoid the risk of coronary
obstruction. At the same time, the prosthesis can be
adjusted axially. When the 3 aortic cusps are asym-
metrically calciﬁed, the axial position of the clasper
might be inﬂuenced by the movable connection and
the unique 2-stage deployment, and the coaxial
deployment of the prosthesis can be accomplished.
The structure of the clasper in J-Valve system is
also different from the feelers in JenaValve and the
support frame in Engager. In J-Valve system, there
are 3 straight portions that are 120 apart from each
other in the clasper. They correspond to the native
commissures, whereas the curved portions corre-
spond to the cusps. The aortic annulus and the
clasper form a “lock-and-key” relationship, which
facilitates precise anatomic positioning.
EXPERIENCE WITH TRANSAPICAL IMPLANTATION
OF THE J-VALVE SYSTEM. The technique of trans-
apical implantation of the J-Valve system in pre-
dominant aortic regurgitation is relatively simple. In
our experience, it is critical to determine the diameter
of the annulus accurately before implantation. If the
THV is not adequately oversized, the incidence of
paravalvular leak and valve dislodgment would in-
crease. During the 2-stage implantation, more atten-
tion should be paid to the process of positioning the
prosthesis in the annulus. Occasionally, the edge of
the prosthesis could be trapped by the tip of the
clasper. Ignoring this would result in severe defor-
mation of the clasper as well as paravalvular leak and
valve malposition after the prosthesis is deployed.
We suggest performing a thorough check of the
conﬁguration of the clasper before prosthesis
deployment. If involvement of the clasper is seen,
moving the prosthesis upward, adjusting the align-
ment of the delivery system, and redeploying the
prosthesis could solve this problem easily.
STUDY LIMITATIONS. The research was a non-
randomized observational study with only 6 patients
engaged. The longest follow-up period was limited to
6 months. The future study with more cases and
longer follow-up was scheduled.CONCLUSIONS
Our study demonstrated the feasibility of transapical
implantation of the J-Valve system in high-risk pa-
tients with predominant aortic regurgitation. Proce-
dural and early results of the study on the J-Valve
system performance are promising. Further research
with a larger patient population and longer follow-up
duration are scheduled to conﬁrm the safety and
reliability of its application in predominant aortic
regurgitation.
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